Atherosclerosis 196(1):275282
doi: 10.1111/j.1365-2133.1990.tb06294.x 108 FinamorFEMartinsJRNakanamiDPaivaERMansoPGFurlanettoRP
doi: 10.1038/s41418-018-0127-2 5 Espinosa-OlivaAMde PablosRMSarmientoMVillaranRFCarrillo-JimenezASantiagoMet al
However, after 3 h of treatment, the accumulation of non-targeted NPs NanoSU6668 (ICG) at CNV was significantly lower than that of T-MNS (ICG), and the accumulation of NanoSU6668 (ICG) was significantly reduced after 12 h treatment
Invest Ophthalmol Vis Sci 43 : 18 Andrews DW, Resnicoff M, Flanders AE, Kenyon L, Curtis M, Merli G, Baserga R, Iliakis G, Aiken RD (2001) Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas